Stocks · Health care · Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc.

TARS Clue Score56

United States Fiscal year ends December CIK 0001819790 Results filed 3 Nov 2026

Add to watchlist

What the insiders did Net selling

Individual transactions

Insider

Date

Role

Action

Price

Amount

William J Phd Link

15 Sep 2026

Director

Sold after exercise

$80.01

$5.28K

William J Phd Link

15 Sep 2026

Director

Sold after exercise

759

$79.00

$59.96K

William J Phd Link

15 Sep 2026

Director

Sold after exercise

11,675

$78.33

$914.50K

Bobak R. Azamian

15 Mar 2023

President/CEO and Board Chair

Sold after exercise indirect

8,000

$13.79

$110.32K

Aziz Mottiwala

10 Sep 2021

Chief Commercial Officer

Sold after exercise

2,593

$22.15

$57.43K

Showing 250 of 274 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 304

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 64

Sales straight out of an exercise 5

Sales at will 191

Transactions with no price 0

Shares from compensation/vesting 11,493,487

Sales filed before the plan box existed 99

History held since 20 Oct 2020